The peptide the FDA already voted against

There’s a peptide a lot of people are stacking right now that the FDA has already voted on. Not scheduled to review. Voted. A federal advisory committee sat down with the file, looked at the human safety data, and recommended against it.

You wouldn’t guess that from how this year went. In February a Health Secretary went on the biggest podcast in the world, called himself a big fan of peptides, and said access was coming back. The scene read it as a green light. So it’s worth sitting with the part that didn’t make the clip: if peptides are coming back, why did some of the most popular ones already get a no?

The vote that already happened

CJC-1295. Ipamorelin. The growth-hormone-secretagogue pair half of these stacks are built on. They have already been through this committee — and the committee said no.

Ipamorelin went in front of PCAC on October 29, 2024. CJC-1295 on December 4, 2024, the same day as AOD-9604 and Thymosin Alpha-1. In each case the panel voted against adding the peptide to the 503A bulk drug substances list — the list that decides what a US compounding pharmacy may legally make. The FDA’s reasoning was consistent: insufficient human safety data, mechanistic concerns, and no reproducible efficacy outside small or open-label trials. That’s the state of the human evidence, stated plainly — not a verdict on whether these compounds do anything, but on whether there’s enough human data to compound them legally. Right now there isn’t.

So the coming-back story has a hole in the middle of it. For a real slice of the most-used peptides, the door everyone thinks is opening was already tried, and it didn’t open. A hearing is a decision, not a formality — sometimes it decides against you. Which is the question to carry into the part everyone’s actually watching: the July meeting, and the peptides still in the running.

What the July meeting is actually deciding

The thing that happened in writing came in April, not February. On April 16, 2026, the Federal Register published notice 2026-07361: the FDA scheduling a Pharmacy Compounding Advisory Committee meeting on July 23–24, 2026 to review seven peptides for the 503A bulks list. July 23 takes BPC-157 (reviewed for ulcerative colitis), KPV, TB-500 (wound healing), and MOTs-C. July 24 takes Emideltide — also called DSIP — Semax, and Epitalon (insomnia).

Read those indications again, because they’re the quiet part. BPC-157 is being evaluated for ulcerative colitis, not the shoulder you bought it for. The committee is asked whether to recommend each peptide for a specific named use, and none of the seven is on the docket for the off-label reasons driving most of the demand. So even the best version of July is narrower than the headline made it sound.

How a PCAC review works, and why even a yes in July isn’t a prescription you can fill in August, we covered in what the PCAC review actually is and what happens after the PCAC votes. The short version: PCAC recommends, the FDA then writes the rule, and the honest date a US pharmacy could lawfully fill one of these is a 2027 calendar at the earliest.

The peptide the FDA already voted against is the tell. It’s the proof that a hearing decides, sometimes against you — and that coming back is a direction, not a date. The headline kept the Secretary’s words and dropped the vote that had already happened. The honest version is sharper, and more useful, because it tells you exactly what to watch: not the podcast clip, the docket — and not the docket alone, the rule that has to follow it.

The version worth waiting for is the one a US-licensed pharmacy can lawfully compound for a named indication, on a prescription, with third-party batch testing and your name on the label. That’s the end-state we’re building toward — reading the docket and the rulemaking that follows it, not the clip. Join the waitlist and we’ll tell you the day a peptide you’re tracking actually gets there.